Research Overview
· Last Reviewed April 27, 2026· PSI Editorial Board· IndependentCan Peptides Help My Injury?
The honest picture across 8 injury types — what's been studied, what's been confirmed in humans, and what nobody knows yet.
WHAT ARE YOU INVESTIGATING?
Domain
Animal Studies
Human Trials
Tendon
Achilles, rotator cuff, patellar
Gut / GI
ulcer, colitis, IBD
Knee / joint
chronic pain, post-injury
Ligament
MCL, ankle, sprains
Muscle
tears, strains, atrophy
Peripheral nerve
nerve regeneration
Bone
fracture healing
Skin / wound
topical and systemic
How counts are scaled → · Tap any row to see the studies →
Quick Answer
The animal evidence for several of these compounds is genuinely strong, particularly for tendon, gut, and ligament injuries in BPC-157 studies. The catch is that almost none of this has been confirmed in controlled human trials. Three small uncontrolled BPC-157 studies, all from one Florida clinical group, total fewer than 30 patients. GHK-Cu has rigorous human evidence but only for topical skin use, not deep tissue. None of these compounds is FDA-approved for injury recovery. This page maps what's studied and what isn't, by injury type.
BPC-157 vs TB-500
Two different approaches to the same problem
BPC-157 acts locally. It works at injury sites by promoting new blood vessel formation and growth factor signaling. The Sikiric research group has published well over 100 animal studies showing accelerated tendon, ligament, gut, and neural healing across rats, mice, and other models. The published human evidence is three small uncontrolled studies, all from one Florida clinical group, totaling fewer than 30 patients. The 2024 Vasireddi systematic review of 544 BPC-157 papers found exactly one met methodological inclusion criteria for orthopaedic clinical evidence.
TB-500 acts systemically. It works through actin regulation, enabling cells to migrate toward damaged tissue across the body. The animal evidence covers cardiac, muscle, and wound healing. But TB-500 specifically, the synthetic 17-amino-acid fragment commonly sold on the research-chemical market, has zero published controlled human injury trials. The Phase 2 trials in dry eye (Sosne et al. 2015) and cardiac repair (Zhu 2016, NCT05984134) used full 43-amino-acid Thymosin Beta-4, not TB-500. The two molecules are related but not interchangeable for clinical translation purposes.
Online recommendations to 'stack' BPC-157 and TB-500 together for injury recovery rest on theoretical mechanism complementarity. Local angiogenesis from BPC-157 plus systemic cell migration from TB-500. The rationale sounds reasonable. There is no published controlled human trial of the combination for injury recovery. Lee and Padgett 2021 included a small subset comparing BPC-157 alone versus BPC-157 plus TB-500 for knee pain, but the study was uncontrolled, retrospective, and not designed to evaluate combination superiority.
Both compounds are research-only. Both are WADA-prohibited. Both have animal evidence that significantly exceeds their controlled human evidence. PSI's reading: the animal data is real and worth tracking. Anyone making confident clinical claims about either compound for human tissue repair is reading further into the evidence than the published literature currently supports. The honest framing for both compounds today is 'promising preclinical, almost untested in humans.'
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Across the 5 most-discussed peptides for injury recovery, PSI catalogs the published animal studies and human trials below. None of these compounds has FDA approval for injury recovery.
GHK-Cu
Only compound here with rigorous controlled human evidence, but exclusively for topical skin applications, not injected tissue repair.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Skin / aging wrinkles, firmness, photoaging | 8 Improved collagen production and skin remodeling indicators reported in animal models. | 6 Multiple controlled topical trials reported reduced fine lines, improved firmness, and photodamage repair. All studies used topical (cream) administration. Leyden 2002, Finkey 2005 |
Wound healing topical wound repair | 6 Faster wound closure and improved tissue regeneration reported in animal models of cutaneous injury. | 3 Topical application studies reported faster wound closure and reduced scarring. Topical only. |
Hair restoration androgenetic alopecia | 4 Increased hair follicle size and growth indicators reported in animal models. | 2 Topical formulations reported improved hair density in small controlled trials. |
Tissue repair (systemic) musculoskeletal, internal organs | 5 Effects on inflammatory markers and gene expression (>4,000 genes modulated) reported in animal models. | 0 None published. All controlled human trials of GHK-Cu used topical, not systemic, administration. |
Joint / musculoskeletal tendon, cartilage | 2 Limited animal-model data on direct musculoskeletal application. | 0 None published. |
Thymosin Beta-4
Reached Phase 2 in dry eye and cardiac repair. Not for musculoskeletal injury, and not the same molecule as TB-500.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Dry eye severe ocular surface disease | 6 Improved corneal healing and reduced inflammation reported in animal models of dry eye. | 2 Phase 2 randomized controlled trials reported statistically significant symptom reduction in 9 and 72 patients. |
Cardiac repair post-myocardial infarction | 12 Improved cardiac function and reduced scar formation reported in animal models of myocardial infarction. | 2 Phase 2 pilot in 10 STEMI patients. Phase IIb (n=90) completed 2024, results pending publication. Zhu 2016, NCT05984134 |
Corneal wound epithelial defects | 5 Faster corneal re-epithelialization reported in animal models. | 2 RGN-259 (Thymosin Beta-4 ophthalmic) progressed through Phase 2 and Phase 3 in corneal wound healing. Has not received FDA approval. RegeneRx development program |
Hair follicle stem cell migration | 4 Increased hair follicle stem cell migration reported in animal models. | 0 None published. |
Musculoskeletal injury tendon, ligament, muscle | 6 Improved tissue repair and cell migration reported in animal models. No human translation. | 0 None published. Marketing claims linking Thymosin Beta-4 trials to TB-500 conflate two different molecules. |
Wound healing general cutaneous | 5 Faster wound closure and reduced inflammation reported in animal models. | 0 None published for systemic Thymosin Beta-4 in wound healing. |
BPC-157
The most-discussed peptide for tissue repair. Hundreds of animal studies. Three small uncontrolled human studies totaling fewer than 30 patients, all from one Florida clinical group.
WADA Section S2 prohibition. BPC-157 is prohibited under the World Anti-Doping Agency code. Athletes subject to drug testing should not use this compound.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Tendon Achilles, rotator cuff, patellar | 12 Faster healing and improved biomechanical strength reported in animal models. Vasireddi et al. 2025 systematic review screened 544 papers; 35 met orthopaedic inclusion criteria. | 0 None published. |
Gut / GI tract gastric ulcer, colitis, fistula | 9 Reduced lesion size and faster mucosal healing reported in animal models of GI tract injury. | 1 Phase 2 ulcerative colitis abstract; never published as a full peer-reviewed paper. PL 14736, Sikiric 2005 |
Knee / joint chronic pain, post-injury | 3 Reduced inflammation and tissue-repair indicators reported in animal models. | 1 Retrospective case series, n=16, no placebo control. Subjective knee-pain reduction reported. |
Ligament MCL, ankle, anterior compartment | 8 Earlier fibroblast migration and faster mechanical recovery reported in animal models of ligament injury. | 0 None published. |
Muscle injury and atrophy | 5 Faster functional recovery reported in animal models of muscle injury. | 0 None published. |
Peripheral nerve nerve regeneration | 4 Earlier nerve conduction recovery and improved functional outcomes reported in animal models. | 0 None published. |
Bone fracture healing | 3 Earlier callus formation reported in a small number of animal-model studies. Limited preclinical data. | 0 None published. |
Skin / wound healing topical and systemic | 2 Limited animal-model data on systemic skin and wound healing. | 1 IV safety pilot in 2 healthy adults. No serious adverse events at the doses tested. Lee & Burgess 2025 |
LL-37
Mechanism is solid as the body's own antimicrobial peptide. No interventional human trials for tissue repair.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Antimicrobial defense bacterial, viral, fungal | 15 Direct antimicrobial activity demonstrated in animal models against multiple pathogens. The dominant LL-37 research area. | 0 No interventional human trials of LL-37 as a primary antimicrobial therapy. |
Diabetic wound healing non-healing chronic ulcers | 6 Faster wound closure and increased angiogenesis reported in animal models of diabetic wound healing. | 1 Observational study reported deficient LL-37 expression in chronic non-healing wounds; correlative, not interventional. |
Tissue repair (systemic) musculoskeletal, internal | 4 Effects on tissue repair markers reported in animal models. Limited preclinical data. | 0 None published. |
Cardiovascular atherosclerosis, ischemia | 5 Effects on angiogenesis reported in animal models of cardiovascular disease. | 0 None published. |
Skin / topical wound acute and chronic | 4 Improved wound healing and re-epithelialization reported in animal models of cutaneous injury. | 0 None published. |
TB-500
Zero published controlled human injury trials. The Phase 2 trials cited in marketing used full-length Thymosin Beta-4, not TB-500.
TB-500 is a synthetic 17-amino-acid fragment. Thymosin Beta-4 is the full 43-amino-acid protein. The findings below reflect TB-500-specific literature only. Phase 2 trials cited in TB-500 marketing used Thymosin Beta-4, not TB-500.
WADA Section S2 prohibition. TB-500 is prohibited under the World Anti-Doping Agency code. Athletes subject to drug testing should not use this compound.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Cardiac repair post-myocardial infarction | 4 Animal-model studies of cardiac repair reported improved function. Most published cardiac trials used full Thymosin Beta-4, not TB-500. | 0 None published for TB-500 specifically. |
Wound healing cutaneous, mucosal | 5 Faster wound closure reported in animal models. | 0 None published for TB-500 specifically. |
Muscle recovery exercise-induced damage | 3 Faster muscle recovery reported in animal models. Common athletic-marketing indication. | 0 None published for TB-500 specifically. |
Tendon / ligament soft-tissue injury | 3 Cell migration effects reported in animal models. Limited tendon/ligament-specific data. | 0 None published for TB-500 specifically. |
Cell migration (mechanism) actin sequestration | 4 Cell-migration effects via actin binding reported in cell-culture and animal models. | 0 None published for TB-500 specifically. |
What's Marketed vs What's Studied
6 common claims, corrected.
“BPC-157 is proven to heal tendons in humans.”
Animal tendon data is consistent across multiple studies. No adequately powered controlled human trial has confirmed these results.
“TB-500 and Thymosin Beta-4 are the same compound.”
TB-500 is a 17-amino-acid fragment of the full 43-amino-acid Thymosin Beta-4. Related molecules, not the same compound.
“These peptides are 'natural' and therefore safe.”
Natural origin does not establish safety at therapeutic doses via injection. Dose, route, purity, and duration all require clinical data that largely does not exist.
“Stacking BPC-157 and TB-500 is scientifically validated.”
The stack is based on complementary mechanisms, not controlled evidence. No study has tested the combination.
“GHK-Cu works the same topically and systemically.”
All controlled human GHK-Cu evidence comes from topical skin application. Systemic efficacy for deep tissue has not been tested.
“LL-37 is only an antimicrobial peptide.”
LL-37 also recruits immune cells, induces angiogenesis, and promotes re-epithelialization. It is an immune-modulating peptide, not solely an antibiotic alternative.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Work with a licensed physician who knows this category.
Avoid clinics whose primary business is selling peptides. Look for physicians with sports medicine, regenerative medicine, or orthopedic backgrounds who can evaluate whether peptides are even appropriate for the situation.
Compounding pharmacies must be licensed by the state board.
503A pharmacies prepare patient-specific compounds; 503B outsourcing facilities prepare office-use stock. Both require active state licensure. Verify before any prescription is filled.
Demand third-party HPLC purity testing.
Reputable compounding pharmacies provide certificates of analysis on request. If a supplier cannot produce one, that is the answer.
Require pharmacy-grade sourcing for anything intended for human use.
The minimum standard is a valid prescription, a state-licensed compounding pharmacy, and batch-specific certificates of analysis from an independent testing lab. Any source that cannot meet all three should not be used for human application.
Watching and waiting is a legitimate option.
Conventional injury treatment (physical therapy, eccentric loading, sports medicine evaluation, where indicated PRP or corticosteroid injection) has decades of clinical trial evidence. Peptides do not yet. There is no penalty for being patient.
The regulatory landscape for injury-recovery peptides is dynamic. BPC-157's 2023 Category 2 placement blocked legal compounding, but that status is reversible if a sponsor pursues IND/NDA approval or additional safety data is submitted. TB-500 is not FDA-scheduled but has no approval pathway in progress. The Outsourcing Facilities Association is actively litigating FDA compounding decisions in the Northern District of Texas. Court rulings, new safety submissions, or legislative action could shift the availability of multiple compounds on this page. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
What is the best peptide for injury recovery?
BPC-157 has the broadest preclinical evidence base, with 544 indexed studies across tendon, ligament, muscle, gut, and nerve injury models. However, 'best' depends on the injury type and what evidence standard is acceptable. BPC-157 has the most data but limited human trials. GHK-Cu has human data but primarily for topical skin applications. No compound in this category has completed a large controlled human trial for injury recovery.
Is BPC-157 safe?
BPC-157 has been well-tolerated in the animal studies that constitute the majority of its evidence base. A small number of human studies have not reported serious adverse events. However, long-term safety data at commonly discussed dosages does not exist. No regulatory agency has reviewed BPC-157 for safety in the context of injury recovery.
Can peptides replace surgery for tendon injuries?
No published evidence supports using any peptide as a replacement for surgical intervention when surgery is indicated. Peptides studied for tissue repair are researched as potential adjuncts to standard care, not replacements for it. Surgical decisions should be made by an orthopedic specialist based on imaging and clinical examination.
How long does it take for BPC-157 to work?
Animal studies show measurable effects on tissue repair markers within 7-14 days, with biomechanical improvements at 14-28 days. Human dosing timelines have not been established in controlled trials. Anecdotal reports from the research community vary widely and should not be treated as clinical guidance.
Should I stack BPC-157 and TB-500?
The stacking rationale is mechanistic: BPC-157 increases blood vessel formation and growth factor signaling, while TB-500 enables cell migration toward the injury site. These are non-overlapping mechanisms that could theoretically complement each other. No controlled study has tested the combination. The decision should be discussed with a physician familiar with peptide research.
Is GHK-Cu effective for deep tissue injuries?
GHK-Cu's human evidence comes from topical skin applications, where it has shown efficacy for collagen remodeling and wound healing. Whether these effects translate to deep tissue injuries (tendons, ligaments, internal organs) via systemic administration has not been established in human studies. The gene-expression data supporting over 4,000 gene modulations comes from fibroblast cell cultures.
What does LL-37 do for wound healing?
LL-37 serves a dual function: direct antimicrobial activity against bacteria, fungi, and viruses at wound sites (preventing infection that delays healing), and recruitment of immune cells (monocytes, neutrophils, T cells) that initiate tissue repair. It also promotes angiogenesis and re-epithelialization. Human data exists from chronic wound and diabetic wound-healing studies.
Are these peptides legal?
Regulatory status varies by compound and jurisdiction. None of these peptides is FDA-approved for injury recovery. BPC-157, TB-500, and Thymosin Beta-4 are available as research chemicals. GHK-Cu is available in cosmetic formulations. LL-37 is a research compound. Compounded formulations for human use require a physician prescription and a licensed compounding pharmacy. Regulatory status is not the same as legality, and both vary by country.
What is the difference between TB-500 and Thymosin Beta-4?
TB-500 is a synthetic fragment corresponding to the actin-binding domain (amino acids 17-23) of the full 43-amino-acid Thymosin Beta-4 protein. TB-500 was designed to be more stable and easier to administer than the full protein. Research on Thymosin Beta-4 does not automatically apply to TB-500, though the active domain is shared. Thymosin Beta-4 has been studied in cardiac repair and corneal healing models; TB-500's literature is smaller and focused on general tissue repair.
Do any of these peptides have FDA approval for anything?
No compound covered on this page has FDA approval for injury recovery. Thymosin Beta-4 (via RegeneRx's RGN-259) entered clinical trials for corneal wound healing but has not received FDA approval. LL-37 derivatives have been explored in clinical research for wound management. BPC-157, TB-500, and GHK-Cu have no FDA-approved indications for any use.
How do I verify the quality of a compounded peptide?
Verify three things: (1) the compounding pharmacy holds a valid state pharmacy board license (503A for patient-specific, 503B for office use), (2) third-party analytical testing (HPLC purity, endotoxin, sterility) is performed on each batch and certificates of analysis are available, and (3) the prescribing physician holds a valid medical license and DEA registration. If any of these three cannot be verified, the source should not be used.
What questions should I ask a doctor about peptides for injury recovery?
Ask: (1) Is there an FDA-approved treatment for this specific injury that should be tried first? (2) What evidence level supports the peptide being considered, and is it animal or human data? (3) What is the expected timeline for measurable improvement? (4) What are the risks of delaying established treatment in favor of a research peptide? (5) Can the peptide be used as an adjunct alongside standard care rather than as a replacement?
PSI is an independent research catalog. We don't sell peptides, accept manufacturer funding, or earn commission on physician referrals. Editorial standards →
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.